Abstract
Machine-assisted treatment selection commonly follows one of two paradigms: a fully personalized paradigm which ignores any possible clustering of patients; or a sub-grouping paradigm which ignores personal differences within the identified groups. While both paradigms have shown promising results, each of them suffers from important limitations. In this article, we propose a novel deep learning-based treatment selection approach that is shown to strike a balance between the two paradigms using latent-space prototyping. Our approach is specifically tailored for domains in which effective prototypes and sub-groups of patients are assumed to exist, but groupings relevant to the training objective are not observable in the non-latent space. In an extensive evaluation, using both synthetic and Major Depressive Disorder (MDD) real-world clinical data describing 4754 MDD patients from clinical trials for depression treatment, we show that our approach favorably compares with state-of-the-art approaches. Specifically, the model produced an 8% absolute and 23% relative improvement over random treatment allocation. This is potentially clinically significant, given the large number of patients with MDD. Therefore, the model can bring about a much desired leap forward in the way depression is treated today.
Funder
Ministry of Health, State of Israel
Publisher
Public Library of Science (PLoS)
Reference67 articles.
1. Will precision medicine improve population health?;M Khoury;Jama,2016
2. Precision medicine: from science to value;G Ginsburg;Health Affairs,2018
3. Deep learning opens new horizons in personalized medicine;G. Papadakis;Biomedical Reports,2019
4. Latent variable mixture modelling and individual treatment prediction;R. Saunders;Behaviour Research And Therapy,2020
5. The heterogeneity problem: approaches to identify psychiatric subtypes;E. Feczko;Trends In Cognitive Sciences,2019